Oryzon Genomics S.A. (BME:ORY)

Market Cap	210.84M
Revenue (ttm)	7.36M
Net Income (ttm)	-4.22M
Shares Out	77.51M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	14.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,579
Average Volume	519,993
Open	2.755
Previous Close	2.720
Day's Range	2.685 - 2.790
52-Week Range	1.400 - 3.690
Beta	0.44
RSI	47.07
Earnings Date	Jul 21, 2025

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical developme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ORY

Financial Performance

In 2024, Oryzon Genomics's revenue was $7.62 million, a decrease of -51.43% compared to the previous year's $15.69 million. Losses were -$3.79 million, 2.39% more than in 2023.

Financial numbers in USD